6 results on '"Vijay Barge"'
Number of results to display per page
Search Results
2. Factors associated with mortality among moderate and severe patients with COVID-19 in India: a secondary analysis of a randomised controlled trial
- Author
-
Ashish Sharma, Anand Zachariah, Pankaj Malhotra, Ashish Jain, Priscilla Rupali, Gajanan Sapkal, Aparna Mukherjee, Vivek Kumar, Lakshmanan Jeyaseelan, Neha Singh, John Victor Peter, Anup Agarwal, Gunjan Kumar, Pranab Chatterjee, Tarun Bhatnagar, B Latha, Sunita Bundas, Ravi Dosi, Rosemarie de Souza, Simmi Dube, B Thrilok Chander, Shalini Bahadur, Amit Suri, Aikaj Jindal, Om Shrivastav, Vijay Barge, Archana Bajpayee, Muralidhar Tambe, Nimisha Sharma, Shreepad Bhat, Anil Gurtoo, D Himanshu Reddy, Kamlesh Upadhyay, Tinkal C Patel, Irfan Nagori, Pramod R Jha, C Aparna, Sunil Jodharam Panjwani, Milind Baldi, M Natarajan, Vrushali Khirid Khadke, Seema Dua, Joy John Mammen, Snehil Kumar, Dolly Daniel, Ravindraa Singh, Jayashree Sharma, Yojana A Gokhale, V Saravana Kumar, Himanshu Kaushal, Lovely Thomas, Jess Elizabeth Rasalam, Binila Chacko, Thenmozhi Mani, Melvin Joy, Malathi Murugesan, Janakkumar R Khambholja, Ram S Kaulgud, K V Sreedhar Babu, and Pragya D Yadav
- Subjects
Medicine - Abstract
Objective Large data on the clinical characteristics and outcome of COVID-19 in the Indian population are scarce. We analysed the factors associated with mortality in a cohort of moderately and severely ill patients with COVID-19 enrolled in a randomised trial on convalescent plasma.Design Secondary analysis of data from a Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease.Setting 39 public and private hospitals across India during the study period from 22 April to 14 July 2020.Participants Of the 464 patients recruited, two were lost to follow-up, nine withdrew consent and two patients did not receive the intervention after randomisation. The cohort of 451 participants with known outcome at 28 days was analysed.Primary outcome measure Factors associated with all-cause mortality at 28 days after enrolment.Results The mean (SD) age was 51±12.4 years; 76.7% were males. Admission Sequential Organ Failure Assessment score was 2.4±1.1. Non-invasive ventilation, invasive ventilation and vasopressor therapy were required in 98.9%, 8.4% and 4.0%, respectively. The 28-day mortality was 14.4%. Median time from symptom onset to hospital admission was similar in survivors (4 days; IQR 3–7) and non-survivors (4 days; IQR 3–6). Patients with two or more comorbidities had 2.25 (95% CI 1.18 to 4.29, p=0.014) times risk of death. When compared with survivors, admission interleukin-6 levels were higher (p10 (9.97, 3.65–27.13, p1.0 mg/L (2.50, 1.14–5.48, p=0.022), ferritin ≥500 ng/mL (2.67, 1.44–4.96, p=0.002) and lactate dehydrogenase ≥450 IU/L (2.96, 1.60–5.45, p=0.001) were significantly associated with death.Conclusion In this cohort of moderately and severely ill patients with COVID-19, severity of illness, underlying comorbidities and elevated levels of inflammatory markers were significantly associated with death.Trial registration number CTRI/2020/04/024775.
- Published
- 2021
- Full Text
- View/download PDF
3. Study of immediate and late effects of successful PTMC on left atrial appendage function in patients with severe rheumatic mitral stenosis IN SINUS rhythm
- Author
-
Sumaira Siddiqui, Basheeruddin Ansari, Pravat Kumar Dash, and Vijay Barge
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,RD1-811 ,Left atrial appendage ,Rheumatic mitral stenosis ,Volume overload ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Heart Rate ,Left atrial ,PTMC ,Internal medicine ,medicine ,Humans ,Mitral Valve Stenosis ,Diseases of the circulatory (Cardiovascular) system ,Atrial Appendage ,In patient ,Sinus rhythm ,Heart Atria ,Prospective Studies ,030212 general & internal medicine ,Cardiac Surgical Procedures ,Transesophageal echocardiography ,Mitral stenosis ,Percutaneous transvenous mitral commissurotomy ,business.industry ,Rheumatic Heart Disease ,Atrial fibrillation ,medicine.disease ,Echocardiography, Doppler ,Stenosis ,Treatment Outcome ,RC666-701 ,cardiovascular system ,Cardiology ,Mitral Valve ,Original Article ,Atrial Function, Left ,Female ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Blood Flow Velocity ,Echocardiography, Transesophageal ,Follow-Up Studies - Abstract
Introduction: Since its introduction in 1984, Percutaneous Transvenous Mitral Commissurotomy (PTMC) has become established as a safe and effective treatment for rheumatic Mitral Stenosis (MS).( Ben Farhat et al., 1998) 1 Chronic pressure and volume overload imposed by MS causes left atrial (LA) and Left Atrial Appendage (LAA) dysfunction. Risk of cerebrovascular accident (CVA) is increased approximately 17-fold in patients of MS in Atrial Fibrillation (AF) and is present even in patients of MS in sinus rhythm (SR). This study was undertaken to evaluate the effect of PTMC on LAA function by Trans-esophageal echocardiography (TEE) Doppler and Doppler Tissue Imaging (DTI). Methods: Total 70 cases were enrolled in this study. Patients with symptomatic severe MS (Mitral Valve Area
- Published
- 2020
4. Factors associated with mortality among moderate and severe patients with COVID-19 in India: a secondary analysis of a randomised controlled trial
- Author
-
Yojana A Gokhale, B Thrilok Chander, Amit Suri, Pragya D Yadav, Ravindraa Singh, Anand Zachariah, M Natarajan, Nimisha Sharma, Irfan Nagori, Kamlesh Upadhyay, Sunil J Panjwani, Vrushali Khirid Khadke, Pranab Chatterjee, Jayashree Sharma, Sunita Bundas, Ravi Dosi, Anil Gurtoo, Shalini Bahadur, Ram S Kaulgud, Snehil Kumar, Malathi Murugesan, Vivek Kumar, V Saravana Kumar, Simmi Dube, Himanshu Kaushal, Seema Dua, Rosemarie de Souza, C Aparna, Ashish Jain, Tarun Bhatnagar, John Victor Peter, KV Sreedhar Babu, Om Shrivastav, Binila Chacko, Vijay Barge, B Latha, Aikaj Jindal, Pramod R Jha, Shreepad Bhat, Ashish Sharma, Anup Agarwal, Gunjan Kumar, Lovely Thomas, Lakshmanan Jeyaseelan, Melvin Joy, Neha Singh, Gajanan N. Sapkal, D. Himanshu Reddy, Dolly Daniel, Muralidhar Tambe, Jess Elizabeth Rasalam, Aparna Mukherjee, Archana Bajpayee, Tinkal C Patel, Pankaj Malhotra, Priscilla Rupali, Milind Baldi, Janakkumar R Khambholja, Thenmozhi Mani, and Joy John Mammen
- Subjects
Adult ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,India ,Disease ,law.invention ,Randomized controlled trial ,law ,Secondary analysis ,Internal medicine ,Severity of illness ,Humans ,Medicine ,adult intensive & critical care ,COVID-19 Serotherapy ,SARS-CoV-2 ,business.industry ,Public health ,Immunization, Passive ,COVID-19 ,General Medicine ,Middle Aged ,Cohort ,Breathing ,Public Health ,business - Abstract
ObjectiveLarge data on the clinical characteristics and outcome of COVID-19 in the Indian population are scarce. We analysed the factors associated with mortality in a cohort of moderately and severely ill patients with COVID-19 enrolled in a randomised trial on convalescent plasma.DesignSecondary analysis of data from a Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease.Setting39 public and private hospitals across India during the study period from 22 April to 14 July 2020.ParticipantsOf the 464 patients recruited, two were lost to follow-up, nine withdrew consent and two patients did not receive the intervention after randomisation. The cohort of 451 participants with known outcome at 28 days was analysed.Primary outcome measureFactors associated with all-cause mortality at 28 days after enrolment.ResultsThe mean (SD) age was 51±12.4 years; 76.7% were males. Admission Sequential Organ Failure Assessment score was 2.4±1.1. Non-invasive ventilation, invasive ventilation and vasopressor therapy were required in 98.9%, 8.4% and 4.0%, respectively. The 28-day mortality was 14.4%. Median time from symptom onset to hospital admission was similar in survivors (4 days; IQR 3–7) and non-survivors (4 days; IQR 3–6). Patients with two or more comorbidities had 2.25 (95% CI 1.18 to 4.29, p=0.014) times risk of death. When compared with survivors, admission interleukin-6 levels were higher (p2/FiO2 ratio 10 (9.97, 3.65–27.13, p1.0 mg/L (2.50, 1.14–5.48, p=0.022), ferritin ≥500 ng/mL (2.67, 1.44–4.96, p=0.002) and lactate dehydrogenase ≥450 IU/L (2.96, 1.60–5.45, p=0.001) were significantly associated with death.ConclusionIn this cohort of moderately and severely ill patients with COVID-19, severity of illness, underlying comorbidities and elevated levels of inflammatory markers were significantly associated with death.Trial registration numberCTRI/2020/04/024775.
- Published
- 2021
5. Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)
- Author
-
P Balamanikandan, Pranab Chatterjee, Himanshu Kaushal, Ashish Pathak, Sunil Jodharam Panjwani, Rajendra Madane, Deepti Chourasia, Sohini Arora, Shailja Shukla, Pragya D Yadav, Simmi Dube, Rattiram Sharma, Om Shrivastav, Snehil Kumar, Mayur Jarag, Kairavi Parthesh Joshi, V Saravana Kumar, Pallavi Singh, Ravindranath Reddy K, G Baleswari, Parul Kodan, Clyde D Souza, Medini S, Ketan Kargirwar, Kavita Joshi, Satish Joshi, Purushottam Reddy, Neha Singh, M Sintha, B Latha, Vikash Kavishwar, Tulika Chandra, Pragnesh H Shah, Jayashree Sharma, T Ravi Chandra, Divendu Bhushan, Ravindraa Singh, Puneet Rijhwani, K Chandra Sekhar, Bhabani Prasad Acharya, Rikin Raj, Rekha Hans, Alka Turuk, Pankaj Malhotra, R Sabarinathan, Rajnish Kaushik, Yash Shah, KV Sreedhar Babu, Ram Niwas, Nitin Valvi, Reeni Malik, K Kanagasabai, Vrushali Khirid Khadke, Kavitha Yevoor, Parijat Gogoi, K Tushara Rao, Saurabh Srivastava, Kusum Jashnani, Archit Jain, Vikas Suri, Gowtham Yeeli, Atul Kulkarni, Kamal Malukani, Sheetal Yadav, Anita M. Shete, Anjali Handa, Nirankar Bhutaka, Mamta Shah, Sudhir Bhandari, Govind Rankawat, Jaya Lalwani, M Natarajan, Prerna Sachdeva, Jitendra Patel, Santasabuj Das, Gurpreet Singh, Anil Gurtoo, Sonali Marathe, Maherra Desai, Leena Naik, Nehal M Shah, Gajanan N. Sapkal, Shashikala Sangle, Amit Suri, Milind Baldi, Ajeet Singh, Ram Mohan Jaiswal, Chetan Patil, Vijay Barge, Hemang M Purohit, Tanvi Yardi, Neeraj Kumar, Ashok Yadav, Ashok Pal, Suraj Goyanka, Rajesh Kumar, Asim Das, Darpan Phagiwala, Janak Kumar Khambholja, Niranjan Shiwaji Khaire, Ram S Kalgud, Sangeeta Pahuja, Neeraj Sharma, Saket Shah, Yojana A Gokhale, Mohd Nadeem, Priya Abraham, R Jayanthi, Leena Nakate, Rajesh Karyakarte, UM Sharma, Sonali Salvi, Rakesh Gupta, Pramod R Jha, Monila Patel, D Himanshu Reddy, Rashmi Upadhyay, Mini P Singh, Atish M N, Nikhil Verma, Dattatray Patki, Varun A Bafna, Nilay N Suthar, Ashish Sharma, Anup Agarwal, Smit H Shah, Vipul Tadha, Satyam Arora, K Nagamani, Rashmi Kulkarni, B Suresh Babu, Simran Agrawal, Mayur H Patel, Preksha Dwivedi, B Vengamma, Varsha Godbole, Vijaylakshmi Nag, Divya Kavita, Sanjeev Mishra, Mohith Hn, Raminder Pal Singh, Vinoth Rajendran, Manisha Madkaikar, R S Uma Maheswari, Muralidhar Tambe, Rambha Pathak, K Narsimhulu, Joyce Regi, Shalini Bahadur, Ravi Dosi, Alladi Mohan, Rosemarie de Souza, Akhilesh Kumar Maurya, Kiran Chaudhary, Manoj Kumar Gupta, Rooppreet Kaur Gill, Irfan Nagori, Tushar Madke, Ashish Jain, Rajesh Mahajan, Pankaj J Akholkar, Sunita Bundas, Ritika Sud, Kajal Jarande, Samir Joshi, Anubhav Gupta, Gururaj Rao Deshpande, Manju Purohit, L N Yaddanapudi, Ramesh Waghmare, Pradeep Maurya, Neetu Kukar, Prashanth Gajula, Pvm Lakshmi, Swarupa Bhagwat, Vivek Kumar, Reetika Malik Yadav, Vivek Maleyur, Nitya Wadhwa, Shikha Seth, Tarun Bhatnagar, Mahesh G Solu, Dolly Daniel, P Chandrasekhar, Gunjan Kumar, Devendra K Gupta, David Pradeep Kumar, Nalini Kadgi, Sangita Margam, Swapneil Parikh, Naresh Sachdeva, Venkatesh Dhat, Niteen D Karnik, Fathhur Rabbani, J Vyshnavi, Aparna Mukherjee, Suchet Sachdev, Rashmi Gunjikar, Jayanthi Shastri, JL Marko, Nitu Chauhan, Naveen Gupta, Vrushali Wagh, Shreepad Bhat, Shreevatsa Udupa, Shweta Sharma, Monika Bahl, Ali Wahid, Ranjana Khetrepal, Arti D Shah, M Joseph John, Snehal Shingade, Seema Dua, Kuldeep Kumar Gaur, Archana Bajpayee, Apurv Thakur, Aikaj Jindal, S Ragunanthanan, Ajeet Singh Chahar, Shruti Dogra, Fatema Ezzy, C Aparna, Shivani A. Patel, Srinivasulu Damam, Tehsim Memon, Kamlesh Upadhyay, Nitin Rawat, Rita Saxena, Mahendra Kumar Garg, Tinkal C Patel, Cherry K Shah, B Thrilok Chander, Vishal R Beriwala, Dilip Chawda, Nimisha Sharma, Subash S, Meenakshi Shah, Jaspreet Kaur, Edwin Pathrose, Vijay Kumar, Darshana Rathod, Puneeth Babu Anne, K Hemanth, Shweta Deshmukh, Nidhi Bhatnagar, Anupam Prakash, G K Bohra, Sharda Sharma, Yogesh Agarwal, Nilima Shah, Saurabh Pandey, A Vinaya Sekhar, Rakesh Bhadade, Raja Rao Mesipogu, Manish Barvaliya, Tarak Patel, Rahul J Verma, K Sudha, Joy John Mammen, A Sundararajaperumal, Avtar Singh Dhanju, and Rajni Bassi
- Subjects
medicine.medical_specialty ,Convalescent plasma ,Standard of care ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Outcome measures ,law.invention ,Clinical trial ,Primary outcome ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Open label ,business - Abstract
ObjectivesConvalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19.DesignOpen-label, parallel-arm, phase II, multicentre, randomized controlled trial.SettingThirty-nine public and private hospitals across India.ParticipantsHospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 ≤ 93% on room air).InterventionParticipants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm.Main Outcome MeasureComposite of progression to severe disease (PaO2/FiO2< 100) or all-cause mortality at 28 days post-enrolment.ResultsBetween 22ndApril to 14thJuly 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (13.6%) and 31 (14.6%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: −0.61 to 1.83].InterpretationCP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.Trial registrationThe trial was registered with Clinical Trial Registry of India (CTRI); CTRI/2020/04/024775.
- Published
- 2020
- Full Text
- View/download PDF
6. Study of Left Atrial Appendage Function in Patients of Severe Rheumatic Mitral Stenosis and Effect of Successful PTMC on SEC Grading
- Author
-
Pravat Kumar Dash, Sumaira Siddiqui, Vijay Barge, and Basheeruddin Ansari
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Computer science ,Spontaneous echo contrast ,Rheumatic mitral stenosis ,Physical examination ,General Medicine ,medicine.disease ,Stenosis ,Left atrial ,Internal medicine ,medicine ,Cardiology ,Sinus rhythm ,In patient ,Grading (tumors) - Abstract
Background: Left Atrial Appendage (LAA) dysfunction is common in patients of Mitral stenosis (MS). In the present study we compared the LAA function amongst patients of severe rheumatic MS with particular reference to spontaneous echo contrast (SEC) and evaluated the effect of successful Percutaneous Transvenous Mitral Commissurotomy (PTMC) on SEC grading. Methods: It was a single centre prospective descriptive type of study. Total 75 cases were included during the study period from 2016 to 2020. Symptomatic patients with severe rheumatic mitral stenosis (MVA
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.